{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:56:22Z","timestamp":1761897382748,"version":"build-2065373602"},"reference-count":45,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.clml.2020.08.028","type":"journal-article","created":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T23:08:36Z","timestamp":1600470516000},"page":"e112-e119","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Favorable Outcome After Adjuvant Involved-Field Radiotherapy After Autologous Hematopoietic Stem-Cell Transplantation in Patients With High-Risk Relapsed\/Refractory Lymphoma: A Single-Center Experience"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4773-041X","authenticated-orcid":false,"given":"Panayotis","family":"Kaloyannidis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rawan","family":"Omari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eman","family":"Eldebawy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eshrak","family":"Al Shaibani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Apostolidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taghreed","family":"Hindi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heba","family":"Raslan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayed","family":"Al Garni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Al Buali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalid","family":"Al Anezi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hani","family":"Al Hashmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2020.08.028_bib1","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.bbmt.2011.10.010","article-title":"High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry","volume":"18","author":"Mounier","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2020.08.028_bib2","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsedhemosensitive Hodgkin\u2019s disease: a randomised trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2020.08.028_bib3","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","article-title":"Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin\u2019s disease: results of a BNLI randomised trial","volume":"341","author":"Linch","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2020.08.028_bib4","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.bbmt.2011.07.020","article-title":"Outcomes of Hodgkin\u2019s lymphoma patients with relapse or progression following autologous hematopoietic cell transplantation","volume":"18","author":"Kaloyannidis","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2020.08.028_bib5","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/annonc\/mdx072","article-title":"Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma","volume":"28","author":"Br\u00f6ckelmann","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2020.08.028_bib6","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/sj.bmt.1701894","article-title":"Treatment outcome and prognostic factors for relapse after high-dose chemotherapy and peripheral blood stem cell rescue for patients with poor risk high grade non-Hodgkin\u2019s lymphoma","volume":"24","author":"Lee","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2020.08.028_bib7","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.canrad.2019.02.002","article-title":"The German Hodgkin Study Group risk model is useful for Hodgkin lymphoma patients receiving radiotherapy after autologous stem cell transplant","volume":"23","author":"Furlan","year":"2019","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.clml.2020.08.028_bib8","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ijrobp.2010.05.010","article-title":"Does the addition of involved field radiotherapy to high-dose chemotherapy and stem cell transplantation improve outcomes for patients with relapsed\/refractory Hodgkin lymphoma?","volume":"81","author":"Kahn","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clml.2020.08.028_bib9","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.ijrobp.2018.12.006","article-title":"A\u00a0prospective, multicenter study of involved-field radiation therapy with autologous stem cell transplantation for patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma (ALLG HDNHL04\/TROG 03.03)","volume":"103","author":"Wirth","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clml.2020.08.028_bib10","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1002\/cncr.30482","article-title":"A\u00a0multi-institutional analysis of peritransplantation radiotherapy in patients with relapsed\/refractory Hodgkin lymphoma undergoing autologous stem cell transplantation","volume":"123","author":"Milgrom","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2020.08.028_bib11","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.clml.2017.09.011","article-title":"Consolidative radiotherapy after autologous stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma","volume":"18","author":"Coutu","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2020.08.028_bib12","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ijrobp.2009.04.036","article-title":"Involved field radiation after autologous stem cell transplant for diffuse large B-cell lymphoma in the rituximab era","volume":"77","author":"Biswas","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clml.2020.08.028_bib13","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.radonc.2011.12.031","article-title":"Involved field radiation therapy following high dose chemotherapy and autologous stem cell transplant benefits local control and survival in refractory or recurrent Hodgkin lymphoma","volume":"103","author":"Biswas","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clml.2020.08.028_bib14","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ijrobp.2017.05.007","article-title":"Role of consolidative radiation therapy after autologous hematopoietic cell transplantation for the treatment of relapsed or refractory Hodgkin lymphoma","volume":"99","author":"Wilke","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clml.2020.08.028_bib15","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ijrobp.2015.02.010","article-title":"Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma","volume":"92","author":"Pinnix","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clml.2020.08.028_bib16","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ijrobp.2015.02.030","article-title":"Optimized volumetric modulated arc therapy versus 3D-CRT for early stage mediastinal Hodgkin lymphoma without axillary involvement: a comparison of second cancers and heart disease risk","volume":"92","author":"Filippi","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clml.2020.08.028_bib17","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.bbmt.2019.02.018","article-title":"Risk factors for development of and progression of hepatic veno-occlusive disease\/sinusoidal obstruction syndrome","volume":"7","author":"Corbacioglu","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2020.08.028_bib18","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/sj.bmt.1704759","article-title":"Optimal scheduling to reduce morbidity of involved field radiotherapy with transplantation for lymphomas: a prospective Australasian Leukaemia and Lymphoma Group study","volume":"35","author":"Wirth","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2020.08.028_bib19","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1182\/blood.V95.5.1588.005k38_1588_1593","article-title":"Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors","volume":"95","author":"Krishnan","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.08.028_bib20","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.08.028_bib21","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1093\/annonc\/mdx097","article-title":"International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)","volume":"28","author":"Younes","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2020.08.028_bib22","doi-asserted-by":"crossref","first-page":"596","DOI":"10.3109\/10428194.2011.624227","article-title":"Double high-dose therapy with dose-intensive cyclophosphamide, etoposide, cisplatin (DICEP) followed by high-dose melphalan and autologous stem cell transplantation for relapsed\/refractory Hodgkin lymphoma","volume":"53","author":"Shafey","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2020.08.028_bib23","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.3109\/10428194.2015.1028054","volume":"56","author":"Sakellari","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2020.08.028_bib24","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.ijrobp.2016.05.021","article-title":"Patterns and timing of failure for diffuse large B-cell lymphoma after initial therapy in a cohort who underwent autologous bone marrow transplantation for relapse","volume":"96","author":"Dhakal","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clml.2020.08.028_bib25","doi-asserted-by":"crossref","first-page":"e290","DOI":"10.1016\/j.prro.2018.12.006","article-title":"Patterns of relapse after salvage autologous stem cell transplant for hodgkin\u2019s lymphoma: should sites of relapse relative to initially involved sites be used to guide indications for peri-transplant radiation therapy","volume":"9","author":"Farris","year":"2019","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.clml.2020.08.028_bib26","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.ijrobp.2018.01.011","article-title":"The role of radiation therapy in patients with relapsed or refractory Hodgkin lymphoma: guidelines from the International Lymphoma Radiation Oncology Group","volume":"100","author":"Constine","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clml.2020.08.028_bib27","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.ijrobp.2017.12.005","article-title":"Role of radiation therapy in patients with relapsed\/refractory diffuse large B-cell lymphoma: guidelines from the International Lymphoma Radiation Oncology Group","volume":"100","author":"Ng","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clml.2020.08.028_bib28","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1182\/blood-2014-10-606939","article-title":"Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma","volume":"125","author":"Sauter","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.08.028_bib29","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1182\/blood-2011-10-388058","article-title":"Normalization of pre-ASCT, FDG-PET imaging with second-line, non\u2013cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma","volume":"119","author":"Moskowitz","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.08.028_bib30","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1200\/JCO.2007.15.4773","article-title":"Involved-field radiotherapy before high-dose therapy and autologous stem-cell rescue in diffuse large-cell lymphoma: long-term disease control and toxicity","volume":"26","author":"Hoppe","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.08.028_bib31","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.ijrobp.2017.01.222","article-title":"Accelerated total lymphoid irradiation-containing salvage regimen for patients with refractory and relapsed Hodgkin lymphoma: 20 years of experience","volume":"97","author":"Rimner","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clml.2020.08.028_bib32","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/COC.0b013e3182880b9f","article-title":"Contribution of involved-field radiotherapy to survival in patients with relapsed or refractory Hodgkin lymphoma undergoing autologous stem cell transplantation","volume":"38","author":"Eroglu","year":"2015","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.clml.2020.08.028_bib33","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.bbmt.2006.06.006","article-title":"Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin\u2019s lymphoma","volume":"12","author":"Majhail","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2020.08.028_bib34","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1093\/annonc\/mdi248","article-title":"High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin\u2019s lymphoma: results of a multicenter phase II study","volume":"16","author":"Josting","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2020.08.028_bib35","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.08.028_bib36","first-page":"3604","article-title":"Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia","volume":"24","author":"Kalaycio","year":"2006","journal-title":"Clin Oncol"},{"key":"10.1016\/j.clml.2020.08.028_bib37","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1182\/blood-2002-04-1261","article-title":"Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case\u2013control study","volume":"101","author":"Metayer","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.08.028_bib38","doi-asserted-by":"crossref","first-page":"863","DOI":"10.3109\/10428190109097705","article-title":"Bone marrow stromal damage after chemo\/radiotherapy: occurrence, consequences and possibilities of treatment","volume":"42","author":"Banfi","year":"2001","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2020.08.028_bib39","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.stem.2017.07.004","article-title":"Long-term engraftment of primary bone marrow stromal cells repairs niche damage and improves hematopoietic stem cell transplantation","volume":"21","author":"Abbuehl","year":"2017","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.clml.2020.08.028_bib40","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s00277-018-3231-y","article-title":"Total body irradiation tremendously impair the proliferation, differentiation and chromosomal integrity of bone marrow\u2013derived mesenchymal stromal stem cells","volume":"97","author":"Lo","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2020.08.028_bib41","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1634\/theoncologist.2017-0499","article-title":"Autologous stem cell transplantation in elderly lymphoma patients in their 70s: outcomes and analysis","volume":"23","author":"Sun","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2020.08.028_bib42","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/j.bbmt.2014.08.019","article-title":"Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma","volume":"20","author":"Dahi","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2020.08.028_bib43","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.bbmt.2017.06.014","article-title":"Hematopoietic cell transplantation\u2013specific comorbidity index predicts morbidity and mortality in autologous stem cell transplantation","volume":"3","author":"Berro","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2020.08.028_bib44","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/j.bbmt.2016.06.007","article-title":"Comorbidities, alcohol use disorder, and age predict outcomes after autologous hematopoietic cell transplantation for lymphoma","volume":"22","author":"Graf","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"author":"Plecher","key":"10.1016\/j.clml.2020.08.028_bib45"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502030519X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502030519X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:36:33Z","timestamp":1761870993000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226502030519X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S215226502030519X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2020.08.028","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Favorable Outcome After Adjuvant Involved-Field Radiotherapy After Autologous Hematopoietic Stem-Cell Transplantation in Patients With High-Risk Relapsed\/Refractory Lymphoma: A Single-Center Experience","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2020.08.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}